130 related articles for article (PubMed ID: 29988078)
1. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
Issa AM; Thorogood A; Joly Y; Knoppers BM
Genet Med; 2019 Mar; 21(3):542-544. PubMed ID: 29988078
[No Abstract] [Full Text] [Related]
2. Discussion: The FDA is Unprepared for Personalized Medicine.
Tabarrok A
Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317
[No Abstract] [Full Text] [Related]
3. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
[TBL] [Abstract][Full Text] [Related]
4. Toward a Personalized Use of Paclitaxel.
Russo GL
Recent Pat Anticancer Drug Discov; 2019; 14(4):296-297. PubMed ID: 31920185
[No Abstract] [Full Text] [Related]
5. Discussion: The role, position, and function of the FDA-The past, present, and future.
Fleming TR; Demets DL; McShane LM
Biostatistics; 2017 Jul; 18(3):417-421. PubMed ID: 28633307
[No Abstract] [Full Text] [Related]
6. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
7. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
8. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
[TBL] [Abstract][Full Text] [Related]
9. Regulations, economics hindering adoption of personalized medicine.
Thompson CA
Am J Health Syst Pharm; 2011 Mar; 68(5):372-4. PubMed ID: 21330674
[No Abstract] [Full Text] [Related]
10. Carvedilol and the Food and Drug Administration approval process: an introduction.
Fisher LD; Moyé LA
Control Clin Trials; 1999 Feb; 20(1):1-15. PubMed ID: 10027497
[TBL] [Abstract][Full Text] [Related]
11. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
12. Pharmacogenomic data: FDA voluntary and required submission guidance.
Salerno RA; Lesko LJ
Pharmacogenomics; 2004 Jul; 5(5):503-5. PubMed ID: 15212586
[No Abstract] [Full Text] [Related]
13. Ensuring that accelerated approvals benefit patients.
The Lancet Haematology
Lancet Haematol; 2021 Sep; 8(9):e613. PubMed ID: 34450093
[No Abstract] [Full Text] [Related]
14. US FDA feels the heat from Congressional hearings.
Loewenberg S
Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
[No Abstract] [Full Text] [Related]
15. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
DeLoughery EP; Prasad V
Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
[No Abstract] [Full Text] [Related]
16. FDA drug-review, surveillance processes under scrutiny.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
[No Abstract] [Full Text] [Related]
17. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider.
Misbin RI
Diabetes Care; 2005 Oct; 28(10):2573-6. PubMed ID: 16186303
[No Abstract] [Full Text] [Related]
18. When it takes two to tango, FDA suggests a new regulatory dance.
Dolgin E
Nat Med; 2011 Mar; 17(3):270. PubMed ID: 21383727
[No Abstract] [Full Text] [Related]
19. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
Dougherty MK; Zineh I; Christl L
Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
[TBL] [Abstract][Full Text] [Related]
20. Two-stage drug approval would reduce the risks.
Frantz JA
Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
